Myriad Genetics Inc
MYGN3.890USD
-0.140-3.47%
Cierre 05/09, 16:00（ET）Cotizaciones retrasadas 15 min
358.66MCap. mercado
PérdidaP/E TTM
Más Datos de Myriad Genetics Inc Compañía
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Información de la empresa
Código de la empresaMYGN
Nombre de la empresaMyriad Genetics Inc
Fecha de salida a bolsaOct 06, 1995
Fundada en1992
Director ejecutivoMr. Samraat S. (Sam) Raha
Número de empleados2700
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 06
Dirección322 North 2200 West
CiudadSALT LAKE CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal84116
Teléfono18015843600
Sitio Webhttps://myriad.com/
Código de la empresaMYGN
Fecha de salida a bolsaOct 06, 1995
Fundada en1992
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
82.34K
--
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
77.39K
--
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Chief Legal Officer
Chief Legal Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
82.34K
--
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
77.39K
--
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Hereditary Cancer
364.50M
43.52%
Prenatal
177.10M
21.14%
Pharmacogenomics
170.20M
20.32%
Tumor Profiling
125.80M
15.02%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
769.50M
91.87%
Rest of world
68.10M
8.13%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Hereditary Cancer
364.50M
43.52%
Prenatal
177.10M
21.14%
Pharmacogenomics
170.20M
20.32%
Tumor Profiling
125.80M
15.02%
Accionista
Hora de actualización: dom., 4 de may
Hora de actualización: dom., 4 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
11.52%
Wellington Management Company, LLP
6.51%
State Street Global Advisors (US)
5.99%
Millennium Management LLC
4.71%
Other
56.24%
Estadísticas de accionistas
Accionista
Proporción
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
11.52%
Wellington Management Company, LLP
6.51%
State Street Global Advisors (US)
5.99%
Millennium Management LLC
4.71%
Other
56.24%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
43.56%
Investment Advisor
34.86%
Hedge Fund
18.62%
Individual Investor
2.85%
Research Firm
2.64%
Pension Fund
1.14%
Bank and Trust
0.40%
Sovereign Wealth Fund
0.10%
Insurance Company
0.04%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
510
96.13M
104.30%
-2.66M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
2023Q1
483
85.87M
105.37%
-2.69M
2022Q4
490
83.72M
103.14%
-4.93M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
14.32M
15.68%
+446.35K
+3.22%
Dec 31, 2024
The Vanguard Group, Inc.
10.57M
11.58%
+279.38K
+2.71%
Dec 31, 2024
Wellington Management Company, LLP
6.00M
6.58%
-711.99K
-10.60%
Dec 31, 2024
State Street Global Advisors (US)
5.53M
6.05%
+822.26K
+17.48%
Dec 31, 2024
Millennium Management LLC
4.35M
4.76%
-831.32K
-16.06%
Dec 31, 2024
Glenview Capital Management, LLC
4.16M
4.55%
+2.90M
+229.55%
Dec 31, 2024
EARNEST Partners, LLC
3.97M
4.35%
+15.65K
+0.40%
Dec 31, 2024
Camber Capital Management LP
3.10M
3.4%
-850.00K
-21.52%
Dec 31, 2024
Artisan Partners Limited Partnership
2.77M
3.03%
+336.77K
+13.86%
Dec 31, 2024
Disciplined Growth Investors, Inc.
2.56M
2.8%
+29.14K
+1.15%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: mar., 6 de may
Hora de actualización: mar., 6 de may
Nombre
Proporción
Invesco Biotechnology & Genome ETF
1.95%
Global X Genomics & Biotechnology ETF
1.64%
WisdomTree BioRevolution Fund
0.64%
Invesco S&P SmallCap Health Care ETF
0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.31%
SPDR S&P Biotech ETF
0.27%
Strategas Global Policy Opportunities ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Inspire Small/Mid Cap ESG ETF
0.14%
SPDR S&P 600 Small Cap Value ETF
0.12%
Ver más
Invesco Biotechnology & Genome ETF
Proporción1.95%
Global X Genomics & Biotechnology ETF
Proporción1.64%
WisdomTree BioRevolution Fund
Proporción0.64%
Invesco S&P SmallCap Health Care ETF
Proporción0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.31%
SPDR S&P Biotech ETF
Proporción0.27%
Strategas Global Policy Opportunities ETF
Proporción0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.17%
Inspire Small/Mid Cap ESG ETF
Proporción0.14%
SPDR S&P 600 Small Cap Value ETF
Proporción0.12%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos